Eylem Pınar Eser

Eylem Pınar Eser

Auto-generated profile, based on publicly available information

Eylem Pınar Eser

Department of Pathology Ankara Etlik City Hospital Türkiye

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
KKKoray Koşmaz
Koray Koşmaz
ADAbdullah Durhan
Abdullah Durhan
MSMarlen Süleyman
Marlen Süleyman
YÜYılmaz Ünal
Yılmaz Ünal
MBMustafa Taner Bostanci
Mustafa Taner Bostanci
SHSema Hücümenoğlu
Sema Hücümenoğlu
Background/aims: To evaluate the potential protective effects of Ankaferd blood stopper (ABS) in an experimental obstructive jaundice (OJ) model. Materials and methods: The study included 26 female rats, which were divided into 3 groups. The sham group, consisting of 10 rats, (group 1) only received solely laparotomy. In the control group, consisting of 8 rats, (group 2), ligation was applied to the biliary tract and no treatment was implemented. In the treatment group, consisting of 8 rats, (group 3), following ligation of biliary tract, 0.5 mL/day ABS was given for 10 days. Liver tissue and blood samples were taken for histopathological and biochemical examination. Results : Compared to group 2, group 3 had higher aspartate aminotransferase (AST), total oxidant status (TOS) malondialdehyde (MDA), fluorescent oxidant products (FOP), and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). In histopathological analysis, the mean scores of all histopathological parameters (fibrosis, portal inflammation, confluent necrosis, interphase activity, bile duct proliferation) have statistical significance between group 2 and group 3 (P < 005). Conclusions: ABS has promising results in the treatment of experimental OJ because of its antioxidant and antiinflammatory properties. It may be used in clinical practice after more extensive studies about the effects of ABS on OJ.

31 January 2022 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
EDEngin Doğantekin
Engin Doğantekin
TATurgay Akgül
Turgay Akgül
EEEylem Pınar Eser
Eylem Pınar Eser
MKMustafa Kotanoğlu
Mustafa Kotanoğlu
VBVeysel Bayburtluoğlu
Veysel Bayburtluoğlu
SHSema Hücümenoğlu
Sema Hücümenoğlu

1 November 2009 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
KSKaan Sönmez
Kaan Sönmez
ZTZafer Türkyılmaz
Zafer Türkyılmaz
RKRamazan Karabulut
Ramazan Karabulut
AKAlparslan Kapisiz
Alparslan Kapisiz
EEEylem Pınar Eser
Eylem Pınar Eser
ABA. Can Başaklar
A. Can Başaklar

23 June 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
SKSüleyman Karaköse
Süleyman Karaköse
ABAyşe Zeynep BAL
Ayşe Zeynep BAL
EEEylem Pınar Eser
Eylem Pınar Eser
MDMurat Duranay
Murat Duranay
Background/aim: Peritoneal sclerosis may be observed in varied manifestations. However, the most serious form is the encapsulated peritoneal sclerosis. We researched the effect of rituximab on peritoneal fibrosis in an experimental rat model. Materials and methods: Twenty-four Wistar Albino rats were divided into 4 equal groups. During weeks 0-3; group I received isotonic saline (IS) solution, group II, group III, and group IV received chlorhexidine gluconate (CG) via intraperitoneal (i.p.) route. In the next 3 weeks nothing adminestred to both group I and group II but IS solution was adminestred to group III via i.p. route and 375 mg/m2/week rituximab was applied intravenously on days 21, 28, and 35 to group IV. Fibrosis, peritoneal thickness, and inflammation were evaluated. Immunohistochemical methods used for the detection of matrix MMP-2, TGF-beta 1, and VGEF expressions. Results: The rituximab (group IV) had significantly lower fibrosis and peritoneal thickness scores than the group II and III (P < 0.001). TGF-beta 1 and VEGF expressions were significantly lower in the rituximab group than in the group II and III (P < 0.001). Conclusion: We found that rituximab had a significant effect on the peritoneal thickness, total fibrosis, TGF-beta 1 and VGEF scores which were induced by CG.

5 May 2020 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
ADAbdullah Durhan
Abdullah Durhan
KKKoray Koşmaz
Koray Koşmaz
MSMarlen Süleyman
Marlen Süleyman
MTMesut Tez
Mesut Tez
AŞAbdullah Şenli̇kCi̇
Abdullah Şenli̇kCi̇
SHSema Hücümenoğlu
Sema Hücümenoğlu
Background/aim: To investigate possible protective effects of Ankaferd Blood Stopper (R) (ABS) in an experimental liver ischemia reperfusion injury (IRI) model. Materials and methods: The study was carried out on 30 female rats separated into 3 groups as sham, control (IRI), and treatment (IRI + ABS) groups. In the IRI + ABS group, 0.5 mL/day ABS was given for 7 days before surgery. In the IRI and IRI + ABS groups, the hepatic pedicle was clamped for 30 min to apply ischemia. Then, after opening the clamp, 90-min reperfusion of the liver was provided. Blood and liver tissue samples were taken for biochemical and histopathological analyses. Results: Compared to the sham group, the IRI group had significantly higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total oxidant status (TOS), malondialdehyde (MDA), fluorescent oxidant products (FOP) and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). Compared to the IRI group, the IRI+ABS group showed lower expression of AST, ALT, TOS, MDA and FOP and higher expression of albumin and TAS (P < 0.05). In the histopathological analysis, congestion scores were statistically significantly lower in the IRI + ABS group than in the IRI group. Conclusions: ABS has a strong hepatoprotective effect due to its antioxidant and antiinflammatory effects and could therefore be used as a potential therapeutic agent for IRI.

28 March 2021 in Journal of Health Sciences and Medicine
Verified
Journal Article
Open access
PDF file
ADAbdullah Durhan
Abdullah Durhan
KKKoray Koşmaz
Koray Koşmaz
AŞAbdullah Şenli̇kci̇
Abdullah Şenli̇kci̇
EEEnder Ergüder
Ender Ergüder
MSMarlen Süleyman
Marlen Süleyman
SHSema Hücümenoğlu
Sema Hücümenoğlu
Aim: This experimental study aimed to evaluate the hepatoprotective effect on obstructive jaundice (OJ) of oral red ginseng (RG) extract, which is known to have anti-inflammatory and antioxidant properties. Methods: The rats were randomly separated into 3 groups of 10 rats: the sham group, the control group, and the treatment group. In Group 1 (sham), the common bile duct (CBD) was identified but no ligation or transection was performed. In Group 2 (control), the CBD was identified and ligation and transection were performed, but no treatment was given. In Group 3 (RG group), CBD ligation and transection were performed, then RG extract was administered via an orogastric tube at a dose of 100 mg/ kg/day for 10 days. After 10 days, blood samples were taken for biochemical analysis, and liver tissue samples for biochemical and histopathological analysis. Results: Significantly higher serum albumin levels and lower serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined in the RG group than in the control group (p = 0.028, p = 0.001 and p = 0.034, respectively). In the oxidative stress parameters, malondialdehyde (MDA) levels and catalase (CAT) levels were significantly different between the RG group and control group (p = <0.001 for each). Total sulfhydryl (T-SH) was not at a statistically significant level, although it was high and approached the value of the sham group ( p = 0.076). In the histopathological evaluation, the RG group had statistically significantly lower scores in all parameters compared to the control group (p<0.05). Conclusion: The results of this study showed that RG has a strong hepatoprotective effect as a result of its anti-inflammatory and antioxidant properties.